1. Report Introduction 2. Non Alcoholic Fatty Liver Disease (NAFLD) Market Overview at a Glance 2.1. Market Share Distribution of Non Alcoholic Fatty Liver Disease (NAFLD) in 2016 2.2. Market Share Distribution of Non Alcoholic Fatty Liver Disease (NAFLD) in 2028 3. Disease Background and Overview: Non Alcoholic Fatty Liver Disease (NAFLD) 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM 4.3. Total Prevalent Patient Population of Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM – By Countries 5. Epidemiology of Non Alcoholic Fatty Liver Disease (NAFLD) by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.1.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.1.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.1.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.1.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.4.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.4.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.4.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.4.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.5.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.5.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.5.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.5.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.6.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.6.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.6.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.6.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.7.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.7.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.7.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.7.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.8.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.8.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.8.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.8.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.9.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.9.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) * 5.9.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 5.9.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Non Alcoholic Fatty Liver Disease (NAFLD) 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Non Alcoholic Fatty Liver Disease (NAFLD) 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Non Alcoholic Fatty Liver Disease (NAFLD) : 7MM Market Analysis 12.1. 7MM Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) 12.2. 7MM Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) 12.3. 7MM Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products 13. Non Alcoholic Fatty Liver Disease (NAFLD) : Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in United States 13.1.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in United States 13.1.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in Germany 13.2.1.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in Germany 13.2.1.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in France 13.2.2.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in France 13.2.2.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in Italy 13.2.3.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in Italy 13.2.3.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in Spain 13.2.4.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in Spain 13.2.4.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in United Kingdom 13.2.5.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in Japan 13.3.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in Japan 13.3.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight *Indication Specific

Table 1: Total Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM Table 2: Total Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM by Countries Table 3: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Table 4: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Table 5: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Table 6: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Table 7: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Table 8: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Table 9: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Table 10: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Table 11: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Table 12: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Table 13: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Table 14: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Table 15: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Table 16: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Table 17: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Table 18: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Table 19: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Table 20: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Table 21: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Table 22: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Table 23: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Table 24: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Table 25: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Table 26: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Table 27: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Table 28: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Table 29: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Table 30: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Table 31: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Table 32: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Table 33: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Table 34: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Table 35: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Table 36: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Table 37: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Table 42:7MM- Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 43:7MM- Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 44: United States-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Table 45: United States-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 46: United States-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 47: Germany-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Table 48: Germany-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 49: Germany-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 50: France-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Table 51: France-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 52: France-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 53: Italy-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Table 54: Italy-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 55: Italy-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 56: Spain-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Table 57: Spain-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 58: Spain-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 59:UK-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Table 60:UK-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 61:UK-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 62: Japan-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Table 63: Japan-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Table 64: Japan-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 1: Total Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM Figure 2: Total Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Figure 4: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Figure 5: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Figure 6: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Figure 7: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028) Figure 8: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Figure 9: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Figure 10: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Figure 11: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Figure 12: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028) Figure 13: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Figure 14: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Figure 15: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Figure 16: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Figure 17: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028) Figure 18: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Figure 19: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Figure 20: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Figure 21: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Figure 22: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028) Figure 23: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Figure 24: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Figure 25: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Figure 26: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Figure 27: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028) Figure 28: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Figure 29: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Figure 30: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Figure 31: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Figure 32: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028) Figure 33: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Figure 34: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Figure 35: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Figure 36: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Figure 37: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Figure 42:7MM- Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 43:7MM- Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 44: United States-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Figure 45: United States-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 46: United States-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 47: Germany-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Figure 48: Germany-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 49: Germany-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 50: France-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Figure 51: France-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 52: France-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 53: Italy-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Figure 54: Italy-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 55: Italy-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 56: Spain-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Figure 57: Spain-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 58: Spain-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 59:UK-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Figure 60:UK-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 61:UK-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 62: Japan-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028) Figure 63: Japan-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028) Figure 64: Japan-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)